skin cancer

With the accreditation, the La Jolla, California-based molecular dermatology firm can provide its services in all 50 states and the District of Columbia.

Teams studying kidney and skin cancers independently implicated SWI/SNF chromatin remodeling mutations in checkpoint blockade immunotherapy response.

As part of the approval, DermTech will market and sell the pigmented lesions assay in Canada, while samples will be processed at the company's lab in California.

Despite the initial high cost, the firm believes the assay's improved accuracy and sensitivity will sway clinical and payor interest.

Researchers identified rises and declines in disease risk that appeared to coincide with the proportion of ancestry from Mapuche and Aymara populations.

A genome-wide association study and meta-analysis uncovered several possible ties to multiple keratinocyte cancer versus single keratinocyte cancer cases.

This Week in Science

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.

The study confirmed 17 previously identified loci, and uncovered 14 new ones that researchers hope can improve understanding of BCC pathogenesis and inform strategies for prevention.

An international team has uncovered roles for MYCN, PTPN14, and LATS1 mutations in the development and progression of skin basal cell carcinoma.

An analysis of angiosarcoma-derived cell lines identified a NUP160-SLC43A3 fusion that subsequently turned up in aggressive primary tumor samples.


An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.